Cargando…
A clinical follow‐up of omalizumab in routine treatment of allergic asthma monitored by CD‐sens
INTRODUCTION: Omalizumab has been available for treatment of allergic asthma for more than a decade and thus, its efficacy in routine treatment was of interest to evaluate. Basophil allergen threshold sensitivity (CD‐sens) has been shown to correlate with the bronchial allergen threshold sensitivity...
Autores principales: | Johansson, S. Gunnar O., Lilja, Gunnar, Hallberg, Jenny, Nopp, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113766/ https://www.ncbi.nlm.nih.gov/pubmed/29737044 http://dx.doi.org/10.1002/iid3.225 |
Ejemplares similares
-
Successful management of severe cow's milk allergy with omalizumab treatment and CD-sens monitoring
por: Nilsson, Caroline, et al.
Publicado: (2014) -
Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018) -
In search of clinically relevant parameters to monitor successful omalizumab therapy in allergic asthma
por: Probst, M., et al.
Publicado: (2019) -
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017) -
Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)